<DOC>
	<DOCNO>NCT03035253</DOCNO>
	<brief_summary>The purpose study test safety efficacy experimental drug , OMP-305B83 , give combination FOLFIRI . OMP-305B83 humanize bispecific monoclonal antibody develop target cancer stem cell . Based preclinical study , believe OMP-305B83 may block growth cancer stem cell may also impair productive growth new blood vessel , tumor need grow spread . The study sponsor OncoMed Pharmaceuticals , refer OncoMed Sponsor .</brief_summary>
	<brief_title>A Study OMP-305B83 Subjects With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>This open-label , Phase 1b dose escalation expansion study OMP-305B83 plus FOLFIRI evaluate safety , efficacy , pharmacokinetics OMP-305B83 combination FOLFIRI patient metastatic Colorectal Cancer . This study consist screen period , treatment period , post-treatment follow-up period patient follow survival 5 year . Patients enrol two stage : dose-escalation stage expansion phase .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>Measurable disease per response evaluation criterion solid tumor ( RECIST ) v1.1 Age &gt; 21 year Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate organ marrow function For woman childbearing potential men partner childbearing potential , agreement ( patient and/or partner ) use two effective form contraception study entry least 6 month termination visit . Ability understand willingness sign write informed consent document Receiving investigational agent anticancer therapy Receiving prior hepatic intraarterial chemotherapy Known significant clinically significant gastrointestinal disease Patients brain metastasis ( treat untreated ) leptomeningeal disease , uncontrolled seizure disorder , active neurologic disease Significant intercurrent illness limit patient 's ability participate study may result death next 18 month Pregnant nursing woman Inability comply study follow procedure</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>